Well, I very much welcome the engagement of the MS Society, an organisation that has represented patients with multiple sclerosis so effectively in Wales, and of course their evidence is vitally important to inform us in the considerations of very clear clinical arrangements in terms of the prescribing of drugs. But it is very important that we look particularly to the effect and beneficial impact, and also availability and access in terms of those medications such as Sativex, which you have just raised.

I think your second question also relates to the wider services that we can provide to MS sufferers. Much progress has been made in terms of availability, in terms of research, drugs and appropriate treatment, but it also has to be the wider care pathway as well.